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In 2012 WHO declared a target to eradicate yaws by 2020. The cornerstone of this strategy is community mass
treatment with azithromycin. Initial studies suggest this is a very effective tool that may be capable of interrupt-
ing transmission. Alongside this there has been progress in the development and validation of diagnostic tests for
yaws. Several new challenges have also emerged, in particular, evidence that Haemophilus ducreyi can cause
phenotypically similar ulcers in yaws endemic communities, and evidence for a possible non-human primate res-
ervoir. The 2020 eradication target remains ambitious and more challenges should be expected on the journey.
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In 2012 WHO launched a new strategy for the eradication of
yaws1 supported by World Health Assembly (WHA) resolution
WHA 66.12, which called for global eradication of yaws by
2020. Yaws is predominantly a disease of children and,
untreated, progresses to cause destructive lesions of the skin,
soft tissues and bones. The disease is caused by Treponema
pallidum susbsp. pertenue, a spirochaete closely related to
syphilis,2 and is considered a neglected tropical disease (NTD).
The disease can be treated effectively with a single-dose of
either benzathine-penicillin or azithromycin. Mass treatment
with azithromycin is the mainstay of the new WHO yaws eradi-
cation strategy.
Yaws has been the target of previous eradication efforts.3
Following WHA resolution 2.36, in 1949, a joint WHO/UNICEF
eradication campaign treated more than 50 million individuals
and is thought to have reduced the worldwide prevalence of
yaws by 95%. Despite these successes, yaws eradication was
not achieved. A number of factors contributed to this, including
a failure to achieve adequate coverage of asymptomatic cases
and inadequate surveillance following the completion of the ini-
tial phases of the eradication campaigns. The disease subse-
quently rebounded in a number of countries and despite a
further WHA resolution in 1978 (WHA 31.58),3 and accompany-
ing control efforts, the disease has continued to be a signiﬁcant
public health problem in a number of countries.
Globally yaws is known to be currently endemic in 13 coun-
tries, predominantly in West Africa, South East Asia and the
Paciﬁc.4 For a further 76 countries, which have previously
reported cases of yaws, there are no recent epidemiological
data to guide eradication efforts. Two countries, India and
Ecuador, have reported local interruption of transmission of
yaws following government led elimination efforts.
What are the prospects of achieving global yaws eradication?
The feasibility of achieving eradication depends on biological,
social and political factors.5
Biological factors
A fundamental requirement is the existence of a tool to inter-
rupt transmission. A number of lines of evidence suggest that
such a tool may exist for yaws. Previous eradication efforts
using penicillin have shown that with extremely high coverage it
is possible to interrupt transmission,3 a ﬁnding that has been
conﬁrmed by the recent experience of the Indian yaws elimin-
ation programme.
Will mass treatment with azithromycin be as effective? Initial
pilot data are encouraging and suggest mass treatment with
azithromycin has a signiﬁcant impact on prevalence and trans-
mission of yaws.6 A concern is the potential for emergence of
resistance to azithromycin, now well documented in syphilis.
Surveillance for resistance will be a vital component of yaws
eradication efforts.
Adequate surveillance is needed at all stages of an eradica-
tion campaign. Where the clinical features of a disease are sen-
sitive and speciﬁc, such as for guinea worm, clinical diagnosis
alone may be sufﬁcient. The clinical phenotype of early yaws is
much less robust. In particular, Haemophilus ducreyi has
recently been shown to be a major cause of similar skin lesions
in yaws endemic communities,7 in some cases accounting for
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more cases than yaws. A rapid serological test has been vali-
dated for yaws but, as H. ducreyi has been found both in sero-
positive and sero-negative individuals, serological diagnosis
alone is unlikely to be sufﬁcient. Access to serological diagnos-
tics, and in the certiﬁcation phase molecular diagnostics, will
need to be scaled-up signiﬁcantly if the eradication target is to
be achieved.
A key requirement for disease eradication is the absence of
an animal reservoir. An emerging body of evidence suggests
there may be a non-human primate (NHP) reservoir for yaws.
Serological and molecular evidence for a disease caused by
T. pallidum has now been documented in NHPs across a range
of countries in Africa, which are currently or formerly endemic
for yaws.8 Alongside this ecological data, there is evidence that
experimental infection of humans with NHPs strains is possible,
and vice versa. Whether zoonotic transmission occurs in the
wild remains an open but vital question.
Social and political factors
Social and political support is of fundamental importance for the
success of any eradication campaign. The WHA resolution is an
important step towards galvanising international political sup-
port for yaws eradication. As a disease predominantly of morbid-
ity not mortality, yaws may not be perceived as a public health
priority even in the countries where it is endemic. Maintaining
political support is likely to become an increasing challenge as
WHO scales up eradication efforts, global case numbers fall but
the costs of on going eradication efforts remain high.
Modelling work suggests that yaws eradication is cost-
effective in the long term and it is hoped that this will help con-
vince donors to support yaws eradication.9 These ﬁndings are
based on a number of assumptions, which may not hold true.
Firstly, the model assumed that transmission would be inter-
rupted everywhere by a limited number of rounds of high cover-
age treatment (90–99% coverage), although there are limited
empirical data to support this. Secondly, data from NTD pro-
grammes shows that such high coverage is rarely achieved in
the real world.10 Finally, the model assumed that only surveil-
lance would be required in all of the formerly endemic countries.
If any of these countries were found to be currently endemic
then the overall costs of yaws eradication may rise sharply.
Finally, many other NTD elimination/eradication programmes
have beneﬁtted from the creation of donation schemes to sup-
port drug and implementation costs. At present no such
donation programme exists for yaws and this represents a sig-
niﬁcant barrier to the scaling up of yaws eradication efforts.
Conclusions
There are four years remaining until the 2020 target for yaws
eradication. At this point it seems unlikely that this target will
be met. The ﬁrst phases of yaws eradication have already
revealed a number of unexpected ﬁndings and it seems likely
that further obstacles will emerge on the road to eradication.
Despite these obstacles, progress has been made in the devel-
opment of new diagnostic tools and pilot studies demonstrating
the effectiveness of azithromycin mass treatment. A sustained
commitment from the WHO, countries and the academic com-
munity will be required if the goal of yaws eradication is to be
achieved.
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